Day: November 14, 2022

Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022. “We continue to achieve important progress in advancing the ongoing REBUILD Phase 3 trial of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD),” said Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors. “With the recent U.S. Food and Drug Administration (FDA) acceptance of the...

NEW YORK and TOKYO, Nov. 14, 2022 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (“HeartCore” or “the Company”), a leading software development company, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 and Recent Operational HighlightsGrew total number of global enterprise customers to 889 as of September 30, 2022. HeartCore’s Content Management System (“CMS”) led Japan in CMS market share for the seventh straight year according to ITR Corporation, an independent IT consulting and research firm. Signed fourth Go IPO consulting service agreement within a six-month period by engaging Metros Development. Entered into a licensing agreement with Transcosmos Digital Technology Inc. to license its advanced process mining tool, Apromore. Hosted HeartCoreDAY2022, a special event focused...

PALM BEACH GARDENS, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) — AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a leading air hygiene technology company, today reported financial results for the three and nine months ended September 30, 2022 (“Q3 2022”). Third Quarter 2022 Highlights and Recent DevelopmentsThe Company entered into a definitive agreement with Molekule, Inc. (“Molekule”), a market leader for premium air purifiers, to combine in an all-stock merger that the Company believes will establish a combined company as a market leader for premium, FDA-cleared air purification products, and solutions. Molekule recently began collaboration with key customers across the US who have deployed thousands of Molekule premium air purifiers throughout portions of their office spaces and enterprises. Post-merger, the...

Revenue Increases 59.1% Year-Over-Year to $5.4 Million for the Third Quarter of 2022 Due to Successful Acquisition Strategy Gross Profit Margin Increases to 49.1% Versus 42.6% for the Same Period Last Year MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) — Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Darren Minton, CEO of Smart for Life, stated, “We continue to successfully implement our acquisition strategy and generate solid year-over-year growth with revenues for Q3 2022 increasing by 59.1% to $5.4 million and revenues for the first 9 months of 2022 increasing by...

BEIJING, Nov. 14, 2022 (GLOBE NEWSWIRE) — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), incorporated in Nevada in September 2014, is a digital technology corporation engaged in three converging and innovative business segments: 5G messaging, acoustic intelligence, and smart city in China, today announced financial results for the first quarter ended September 30, 2022, and provided an update on its key strategic and operational initiatives.  “Our first quarter results delivered performance with sequential improvements in gross profit and revenue versus the same period of 2021, with an increase of 136% in gross profit and an increase of 73% in revenue. Behind the continued strength of our growth, we benefitted from the diversified portfolio and the expanded addressable market, continued productivity efforts and strong...

– SHINE Alzheimer’s Trial Expands to European Sites – – SEQUEL Alzheimer’s Trial Awarded Additional NIA Grant to Complete – – Over 50% of SHIMMER Dementia with Lewy Bodies Study Sites Active – PURCHASE, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) —  Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”) today reported financial results for the third quarter ended September 30, 2022 and provided an update on the company’s business and clinical development progress. “We continue to advance three Phase 2 clinical trials investigating CT1812 and are highly motivated by the encouraging data from our clinical programs as well as favorable results from complementary approaches being pursued by peers in the industry,” said Lisa Ricciardi, president and CEO of Cognition Therapeutics. “With...

Viactiv® Generated Net Revenues of Approximately $2.6 Million or 96% of Net Revenues for the Quarter Ended September 30, 2022 Company Announces Program to Evaluate Strategic Alternatives HOUSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and nine months ended September 30, 2022. The Company also provided a corporate update to stockholders. Financial highlights for the three months ended September 30, 2022 include the following:Revenues were $2,663,550 for the three months ended September 30, 2022, as...

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Recent Corporate DevelopmentsOn November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with Yumanity’s previously announced proposed sale of Yumanity’s lead clinical-stage product candidate, YTX-7739, as well as Yumanity’s unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV (“Janssen”) for $26 million in cash as well as Yumanity’s...

– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast Today at 8:30 a.m. ET – NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) —  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended September 30, 2022. “As announced this morning, we look forward to executing on our revised protocol and statistical analysis plan (SAP) for the Phase 3 registrational REGAL study of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) as well as evaluating the next steps for our ovarian cancer program for GPS in combination with PD1 inhibitors following...